Alkermes, Inc.
New member added to board of directors of biotech
Published in Biotech Law Weekly, July 2nd, 2004
Skaletsky will bring extensive biotechnology and business expertise to the Alkermes board, and he qualifies as an independent director as defined under the Sarbanes Oxley Act of 2002 and the NASDAQ stock exchange regulations.
Skaletsky has more than 30 years of experience serving in executive management positions and leading major growth and acquisition activities for biotech and pharmaceutical companies. Skaletsky is currently chairman, CEO and president of Trine Pharmaceuticals, Inc., a privately held drug development company.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2004-07-02)
More Articles from Biotech Law Weekly
- AMDL, Inc.
Gene therapy may be useful in cancer treatments - Advanced Biotherapy, Inc.
U.S. patent granted for asthma, allergy treatment - Biotechnology
BioShield shortcomings subject of industry conference - Centers for Medicare & Medicaid Services
CMS and NCI collaborate to bring new drugs, better treatment to cancer patients - Centers for Medicare & Medicaid Services
Initiative helps low-income beneficiaries sign up for drug discount card - Centers for Medicare and Medicaid Services
ACCC calls on CMS to allow for exceptions to ASP reimbursement - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
